Syngene International Limited Announces Unaudited Standalone and Consolidated Earnings Results for the Second Quarter and Half Year Ended September 30, 2018
October 25, 2018 at 05:30 am EDT
Share
Syngene International Limited announced unaudited standalone and consolidated earnings results for the second quarter and half year ended September 30, 2018. For the quarter, on standalone basis, the company reported revenue from operations of INR 4,186 million compared to INR 3,352 million a year ago. Total income was INR 4,368 million compared to INR 3,516 million a year ago. profit before tax and exceptional items was INR 966 million compared to INR 944 million a year ago. Profit before tax was INR 966 million compared to INR 944 million a year ago. Profit for the period was INR 782 million compared to INR 769 million a year ago. Basic earnings per share (of INR 10 each) was INR 3.95 compared to INR 3.88 a year ago.
For the half year, on standalone basis, the company reported revenue from operations of INR 8,246 million compared to INR 6,263 million a year ago. Total income was INR 8,616 million compared to INR 8,616 million a year ago. Profit before tax and exceptional items was INR 1,794 million compared to INR 1,704 million a year ago. Profit before tax was INR 1,794 million compared to INR 1,704 million a year ago. Profit for the period was INR 1,442 million compared to INR 1,389 million a year ago. Basic earnings per share (of INR 10 each) was INR 7.29 compared to INR 7.02 a year ago.
For the quarter, on consolidated basis, the company reported revenue from operations of INR 4,186 million. Total income was INR 4,368 million. Profit before tax and exceptional items was INR 968 million. Profit before tax was INR 968 million. Profit for the period was INR 783 million. Basic earnings per share (of INR 10 each) was INR 3.96.
For the half year, on consolidated basis, the company reported operations of INR 8,246 million. Total income was INR 8,616 million. Profit before tax and exceptional items was INR 1,799 million. Profit before tax was INR 1,799 million. Profit for the period was INR 1,445 million. Basic earnings per share (of INR 10 each) was INR 7.30.
Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, and specialty chemical sectors, among others. It operates multi-modal biologics manufacturing facility.
Syngene International Limited Announces Unaudited Standalone and Consolidated Earnings Results for the Second Quarter and Half Year Ended September 30, 2018